StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)

Close on Nov 17, 2026Market cap $50.42MP/E –Yield –

Tonix Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Tonix Pharmaceuticals's total assets was $254.09M at Jun 30, 2026. For fiscal 2025 it was $277.17M, up 70.2% from the year before. Over ten years it grew 19.4% a year on average. The highest annual figure on record is $277.17M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$277.17M+70.2%
FY2024Dec 31, 2024$162.89M+5.5%
FY2023Dec 31, 2023$154.46M-31.6%
FY2022Dec 31, 2022$225.69M-6.3%
FY2021Dec 31, 2021$240.90M+145.4%
FY2020Dec 31, 2020$98.18M+574.4%
FY2019Dec 31, 2019$14.56M-44.7%
FY2018Dec 31, 2018$26.32M-1.6%
FY2017Dec 31, 2017$26.75M-2.7%
FY2016Dec 31, 2016$27.51M-41.5%
FY2015Dec 31, 2015$47.02M+18.9%
FY2014Dec 31, 2014$39.54M+352.6%
FY2013Dec 31, 2013$8.74M+312.7%
FY2012Dec 31, 2012$2.12M+397.6%
FY2011Dec 31, 2011$425.45K+131.2%
FY2010Dec 31, 2010$184.00K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$254.09M+35.6%
Q1 FY2026Mar 31, 2026$257.91M+33.7%
Q4 FY2025Dec 31, 2025$277.17M+70.2%
Q3 FY2025Sep 30, 2025$252.44M+165.8%
Q2 FY2025Jun 30, 2025$187.36M+166.5%
Q1 FY2025Mar 31, 2025$192.87M+42.5%
Q4 FY2024Dec 31, 2024$162.89M+5.5%
Q3 FY2024Sep 30, 2024$94.99M-31.8%
Q2 FY2024Jun 30, 2024$70.31M-56.0%
Q1 FY2024Mar 31, 2024$135.34M-24.4%
Q4 FY2023Dec 31, 2023$154.46M-31.6%
Q3 FY2023Sep 30, 2023$139.28M-42.6%
Q2 FY2023Jun 30, 2023$159.74M-42.2%
Q1 FY2023Mar 31, 2023$179.09M-19.9%
Q4 FY2022Dec 31, 2022$225.69M-6.3%
Q3 FY2022Sep 30, 2022$242.65M+13.0%
Q2 FY2022Jun 30, 2022$276.17M+46.0%
Q1 FY2022Mar 31, 2022$223.72M+21.9%
Q4 FY2021Dec 31, 2021$240.90M+145.4%
Q3 FY2021Sep 30, 2021$214.77M+217.6%
Q2 FY2021Jun 30, 2021$189.17M+224.2%
Q1 FY2021Mar 31, 2021$183.52M+440.8%
Q4 FY2020Dec 31, 2020$98.18M+574.4%
Q3 FY2020Sep 30, 2020$67.62M+451.0%
Q2 FY2020Jun 30, 2020$58.35M+288.8%
Q1 FY2020Mar 31, 2020$33.93M+69.5%
Q4 FY2019Dec 31, 2019$14.56M-44.7%
Q3 FY2019Sep 30, 2019$12.27M-23.6%
Q2 FY2019Jun 30, 2019$15.01M-18.2%
Q1 FY2019Mar 31, 2019$20.02M-4.6%
Q4 FY2018Dec 31, 2018$26.32M-1.6%
Q3 FY2018Sep 30, 2018$16.06M-47.4%
Q2 FY2018Jun 30, 2018$18.36M-48.8%
Q1 FY2018Mar 31, 2018$20.98M-11.8%
Q4 FY2017Dec 31, 2017$26.75M-2.7%
Q3 FY2017Sep 30, 2017$30.54M+2.5%
Q2 FY2017Jun 30, 2017$35.82M–
Q1 FY2017Mar 31, 2017$23.78M–
Q4 FY2016Dec 31, 2016$27.51M–
Q3 FY2016Sep 30, 2016$29.80M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?